Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of the Renal Disease market are centered around addressing the complexities of kidney-related disorders, emphasizing the need for comprehensive solutions and advancements in nephrology. Understanding the multifaceted factors influencing this dynamic healthcare sector is crucial for effective management and treatment of renal diseases.
A major market dynamic is the growing incidence of Chronic Kidney Diseases (CKD), which stands currently as one of the biggest threats. Factors like attaining age, better lifestyles, and increase in diabetes conditions all contributes to the crease in demand for kidney failure management and treatment.
Renal replacement therapy (RRT) being a major prospect in the market, further improvement in RRT modalities especially in dialysis technologies, strongly contributes to the market success. Innovations in the delivery and application of hemodialysis and peritoneal dialysis methods capture the market, leading to better patients results, which is the reason for both the growth and evolution of the market.
The market is influenced by kidney transplant innovations directly or indirectly. The recent improvements in organ preservation, long-term immunosuppressive medication regimens, and expanded living donor programs generally lean toward higher success rates leading the way in renal disease treatment care.
The best prevention and possibly the most prolific of them all is the emphasis on preventive care and early detection, a major factor predominantly in the market. Consequently, public health activities that led to prompt diagnosis of kidney diseases in the first place have been in the frontline leading to mere the existence of suppliers.
The evolution of the market is also dependent on new pharmaceutical developments in renal therapies. New medications for instance, glomerulonephritis and what we call the diabetic nephropathy have been in development. This therefore, leads to diverse treatment options and ultimately affects the competition landscape.
Government policies and market reforms in the area of health care often significant affect the dynamics of the market. Owing to policies on the organ donation, executing the renal treatments with reimbursement handed in, and the initiatives of improving access to healthcare goods also have influences on the renal disease market.
The global nature of organ transplantation requires collaborative efforts. International collaboration in organ donation initiatives, sharing best practices, and addressing barriers to transplantation contribute to a more cohesive global response in the renal disease market.
The focus on patient-centered care and improving the quality of life for individuals with renal diseases is a significant factor in market dynamics. Holistic approaches that address not only medical needs but also psychosocial aspects contribute to shaping the future of renal disease management.
Renal Disease Market Highlights:
Global Renal Disease Market Overview
Renal Disease Market Size was valued at USD 38.10 billion in 2022. The Renal Disease Market industry is projected to grow from USD 42.36 billion in 2023 to USD 89.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.20 % during the forecast period (2023 - 2030). The increasing cases of diabetes & hypertension and the rising prevalence of chronic kidney disease are the key market drivers boosting the growth of the renal disease market.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Renal Disease Market Trends
- Increasing Cases of Diabetes and Hypertension to Boost the Market Growth
Diabetes, hypertension, and kidney failure are three conditions that are closely related and impact each other. The millions of minuscule filtering units within each kidney are damaged over time by excessive amounts of sugar in the blood, leading to kidney failure. According to a report by The International Diabetes Federation (IDF), in March 2020, 13.3% of the total population of the US approximately around 30,987,900 people are diabetic. IDF also predicts that by 2045, the North America and Caribbean (NAC) region will have 63 million diabetic people in the region.
Furthermore, hypertension also negatively impacts proper kidney functioning. Uncontrolled high blood pressure can narrow, weaken, or stiffen the arteries surrounding the kidneys over time. These arteries cannot carry enough oxygenated blood to the renal tissue due to their impairment causing kidney tissue damage. According to the National Kidney Foundation, uncontrolled high blood pressure is the second leading cause of kidney failure in the US. In addition, according to the Centers for Disease Control and Prevention (CDC), hypertension is a primary cause of stroke, heart attack, and renal failure. Hypertension, obesity, diabetes, and heart failure were responsible for 64 % of Covid-19 hospitalizations during the pandemic. Obese people are also more likely to develop hypertension. Therefore, increasing diabetes and hypertension cases across the globe increases the demand for dialysis, anti-hypertensive & diabetes medication, and Kidney transplantation leading to the growth of the renal disease market.
Renal Disease Market Segment Insights
Renal Disease, Disease Type Insights
The renal disease market segmentation, based on disease type, includes chronic kidney disease, and end-stage renal disease. The chronic kidney disease type segment held the majority share in 2022 in respect to the renal disease market revenue. Chronic Kidney Disease (CKD), also called chronic kidney failure, is characterized by loss of kidney function over time. The main risk factors for CKD are high blood pressure, diabetes, and heart disease. According to the National Kidney Foundation, the treatment of chronic kidney disease is likely to exceed USD 48 billion per year in the US.
May 2021 The US Food and Drug Administration (FDA) has approved AstraZeneca’s (UK) Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at risk of progression with and without type-2 diabetes
Renal Disease Treatment Insights
The renal disease market segmentation, based on treatment, includes dialysis, medication, and kidney transplantation. The dialysis segment dominated the market in 2022 in respect to the  renal disease market. Dialysis is the removal of waste products and excess fluid such as water, solutes, and toxins from the blood when the kidneys stop working properly. It is generally performed when 85-90% of kidney function is gone, GFR falls below 15, and kidneys no longer work well enough to sustain a patient’s body. According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2019, more than 661,000 Americans had kidney failure, with 468,000 of those individuals on dialysis. The dialysis segment involves antihypertensive drugs, erythropoiesis-stimulating agents (ESAs), potassium binders, and phosphate binders. Antihypertensive drugs are used to lower the high blood pressure of the patient.
May 2021Â Teva Pharmaceuticals (Israel) launched the first available generic version, in the US, of THIOLA (tiopronin) tablets, indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine (kidney) stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone
Renal Disease End User Insights
The renal disease market segmentation, based on indication includes dialysis centers, hospital & clinics, and research and academic institutes. The dialysis centers held the largest market share in 2022 with respect to the renal disease market revenue. Dialysis centers provide dialysis for patients with chronic kidney failure. In dialysis centers, trained nurses and technicians perform the procedure on patients with renal diseases.
December 2020Â GlaxoSmithKline plc (UK) received the US Food and Drug Administration (FDA) approval for BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy
Figure 2 Renal Disease Market, by End User, 2022 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Renal Disease Regional Insights
By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. North America Renal Disease held the largest market share in 2022. This is attributed to the rising prevalence of kidney disease, the growing prevalence of diabetes and hypertension, and the rapid growth in the geriatric population.
Further, the major countries studied are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 RENAL DISEASE MARKET SHARE (%) BY REGION 2022
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe renal disease market accounts for the second-largest market share due to the increasing healthcare spending, various government initiatives & awareness campaigns regarding CKD, availability of technologically advanced products, and the presence of newly established state-of-the-art healthcare facilities in the region. Further, the Germany renal disease market held the largest market share, and the UK renal disease market was the fastest-growing market in the European region.
The Asia-Pacific renal disease market is expected to grow at a significant growth rate during the forecast period. This is due to the factors, such as growth in the aging population, various lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability are factors expected to boost the market over the forecast period. Moreover, China renal disease market held the largest market share, and the India renal disease market was the fastest-growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2023–2030.
Renal Disease Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the renal disease market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the renal disease industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.Â
One of the primary business strategies adopted by manufacturers in the  renal disease industry to benefit clients and expand the renal disease market sector is to manufacture locally to reduce operating costs.
Akebia Therapeutics Inc. (US) is a trusted leader in the renal community delivering unique products to people suffering from kidney disease. Its product Vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to Vadadustat, the company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Keryx Biopharmaceuticals is a subsidiary of Akebia Therapeutics. For instance, in June 2021, Akebia Therapeutics, Inc. collaborated with Otsuka Pharmaceutical Co., Ltd. (Japan) Ostuka company also announced the US Food and Drug Administration (FDA) accepted filing the New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.
Key Companies in the Renal Disease Market Includes
- Abbott (US)
- Amgen Inc. (US)
- AstraZeneca (UK)
- Bristol-Myers Squibb Company (US)
- Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline PLC (UK)
- Keryx Biopharmaceuticals, Inc. (US)
- Kissei Pharmaceutical Co., Ltd. (Japan)
- Novartis (Switzerland)
Renal Disease Industry Developments
May 2021Â Bristol Myers Squibb (US) declared that OPDIVO (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX (cabozantinib) 40 mg once daily tablets was approved by the US Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
January 2021 Fresenius Medical Care (Germany) announced that the company's Frenova division has enrolled the first participants in Colombia as its new initiative to develop the largest renal-focused genomic registry in the world. The renal-focused genomic registry represents a new business line within Frenova, based in Fresenius Medical Care's  Medical Office
June 2021Â Novartis AG (Switzerland) announced positive new interim Phase II data showing investigational iptacopan (LNP023), a first-in-class, oral, targeted factor B inhibitor improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3 glomerulopathy (C3G) treated with iptacopanÂ
Renal Disease Market Segmentation
Renal Disease Type Outlook
- Chronic Kidney Disease
- End-Stage Renal Disease
Renal Disease Treatment Outlook
- Dialysis
- Medication
- Kidney Transplantation
Renal Disease End User Outlook
- Dialysis Centers
- Hospital & Clinics
- Research and Academic Institutes
Renal Disease Regional Outlook
-
North America- US
- Canada
-
Europe- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
-
Rest of the World- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
